Liminatus Pharma, Inc. Class A Common Stock Cash Flow Conversion Efficiency
Liminatus Pharma, Inc. Class A Common Stock cash flow conversion efficiency. Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a cash flow conversion efficiency ratio of -3.227x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-970.00K) by net assets ($300.61K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
Cash flow conversion efficiency of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025. This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Liminatus Pharma, Inc. Class A Common St for real-time trading data and today's change.
Liminatus Pharma, Inc. Class A Common Stock Cash Flow Conversion Ratio Explained
Liminatus Pharma, Inc. Class A Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Liminatus Pharma, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Liminatus Pharma, Inc. Class A Common Stock ranked by their cash flow conversion efficiency. Also see Liminatus Pharma, Inc. Class A Common St market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gibb River Diamonds Limited
F:PHO
|
-0.230x |
|
Property Franchise Group PLC
LSE:TPFG
|
0.089x |
|
Fairchild Gold Corp
V:FAIR
|
-0.117x |
|
House of Doge Inc.
NASDAQ:HODO
|
-0.184x |
|
Canasil Resources Inc.
V:CLZ
|
-73.065x |
|
PetroFrontier Corp
V:PFC
|
-0.745x |
|
Linkage Global Inc
NASDAQ:UZX
|
N/A |
|
IMMO BLOCKCHAIN EO 1
F:QT5
|
N/A |
Annual Cash Flow Conversion Efficiency for Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025. Review LIMN free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-9.81 Million | $-9.96 Million | 1.015x | +418.60% |
| 2024-12-31 | $-15.87 Million | $-3.11 Million | 0.196x | -37.43% |
| 2023-12-31 | $-10.69 Million | $-3.35 Million | 0.313x | +146.59% |
| 2022-12-31 | $1.29 Million | $-869.00K | -0.671x | -13974.82% |
| 2021-12-31 | $254.87 Million | $-1.22 Million | -0.005x | -- |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.